In addition, another study has found that in non-demented individuals at risk for AD, higher concentrations of disease-associated microglia stage 2 (DAM2) are associated with reduced tau aggregation and alleviated cognitive decline, indicating that activation of microglia to DAM2 can delay the progression of AD (Pereira et al., 2022). Here, MAPT is linked to Alzheimer disease.